Birgit Gaschler-Markefski

Suggest Changes
Learn More
INTRODUCTION The LUME-Lung 1 trial (NCT00805194; Study 1199.13) demonstrated a significant overall survival (OS) advantage for nintedanib plus docetaxel compared with placebo plus docetaxel as(More)